Madrigal Pharmaceuticals IncNASDAQ:MDGL
- LAST PRICE271.6700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots261.0000/ 1
- Ask / Lots283.5000/ 3
- Open / Previous Close273.8100 / 271.6700
- Day Range
- 52 Week Range
- Volume77,460
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MDGL |
|---|---|---|
| 09:32 ET | 667 | 273.81 |
| 09:36 ET | 100 | 273.07 |
| 09:38 ET | 500 | 271.1228 |
| 09:39 ET | 200 | 272.86 |
| 09:41 ET | 1800 | 271.975 |
| 09:57 ET | 890 | 270 |
| 09:59 ET | 200 | 270.175 |
| 10:01 ET | 100 | 271.6 |
| 10:03 ET | 100 | 272.31 |
| 10:10 ET | 100 | 271.65 |
| 10:12 ET | 100 | 271.715 |
| 10:14 ET | 354 | 271.735 |
| 10:15 ET | 100 | 271.735 |
| 10:17 ET | 500 | 272.58 |
| 10:19 ET | 100 | 272.22 |
| 10:21 ET | 100 | 272.015 |
| 10:26 ET | 2600 | 271.2 |
| 10:28 ET | 600 | 269.95 |
| 10:30 ET | 300 | 269.79 |
| 10:35 ET | 100 | 269.905 |
| 10:37 ET | 199 | 269.82 |
| 10:46 ET | 200 | 269.165 |
| 10:48 ET | 111 | 268.61 |
| 10:51 ET | 100 | 269.195 |
| 10:55 ET | 600 | 270.76 |
| 11:00 ET | 100 | 270.98 |
| 11:02 ET | 529 | 271 |
| 11:06 ET | 100 | 272.22 |
| 11:11 ET | 1000 | 270.77 |
| 11:15 ET | 400 | 272.36 |
| 11:18 ET | 100 | 272.385 |
| 11:20 ET | 100 | 271.79 |
| 11:22 ET | 399 | 272.53 |
| 11:31 ET | 200 | 271.015 |
| 11:44 ET | 100 | 269.2 |
| 11:47 ET | 200 | 269.51 |
| 11:49 ET | 100 | 270.17 |
| 11:51 ET | 100 | 269.56 |
| 11:54 ET | 300 | 270.39 |
| 11:56 ET | 200 | 269.78 |
| 12:09 ET | 100 | 271.46 |
| 12:18 ET | 500 | 271.365 |
| 12:20 ET | 350 | 271.096 |
| 12:21 ET | 400 | 272 |
| 12:23 ET | 1496 | 271.31 |
| 12:27 ET | 100 | 271.61 |
| 12:32 ET | 128 | 271.845 |
| 12:34 ET | 200 | 271.665 |
| 12:36 ET | 300 | 272 |
| 12:39 ET | 201 | 271.63 |
| 12:41 ET | 115 | 271.65 |
| 12:43 ET | 200 | 271.84 |
| 12:54 ET | 1600 | 271.45 |
| 12:56 ET | 1600 | 271.93 |
| 12:57 ET | 300 | 271.69 |
| 12:59 ET | 10640 | 271.67 |
Jun 28, 2024
DJ Madrigal Pharmaceuticals Initiated at Neutral by Cantor Fitzgerald, from 7:57AM ET on Friday Jun 28, 2024 by Dow Jones
7:57AM ET on Friday Jun 28, 2024 by Dow Jones
Jun 6, 2024
Jun 5, 2024
Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference, from 8:00AM ET on Wednesday Jun 05, 2024 by Dow Jones
8:00AM ET on Wednesday Jun 05, 2024 by Dow JonesDJ S&P 500 Futures Rise In Premarket Trading; Hewlett Packard Ent, CrowdStrike Holdings Lead, from 7:30AM ET on Wednesday Jun 05, 2024 by Dow Jones
7:30AM ET on Wednesday Jun 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Madrigal Pharmaceuticals Inc | 5.8B | -11.8x | --- |
Viking Therapeutics Inc | 5.7B | -54.2x | --- |
Revolution Medicines Inc | 6.2B | -9.8x | --- |
Summit Therapeutics Inc | 5.3B | -41.6x | --- |
Cytokinetics Inc | 6.4B | -10.1x | --- |
Krystal Biotech Inc | 5.1B | 94.3x | --- |
Company Information
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Contact Information
- Headquarters
- 200 Barr Harbor Dr Ste 400WEST CONSHOHOCKEN, PA, United States 19428-2978
- Phone
- 404-380-9263
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Julian Baker
- President, Chief Executive Officer, Director
- Bill Sibold
- Chief Financial Officer, Senior Vice President
- Mardi Dier
- President of Research and Development, Chief Medical Officer, Director
- Rebecca Taub
- Chief Commercial Officer
- Carole Huntsman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.8B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 21.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.42 |
EPS | $-23.08 |
Book Value | $20.39 |
P/E Ratio | -11.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
